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Abstract
Background: Surgery for type II SLAP (superior labral anterior posterior) lesions of the shoulder is a promising but
unproven treatment. The procedures include labral repair or biceps tenodesis. Retrospective cohort studies have
suggested that the benefits of tenodesis include pain relief and improved function, and higher patient satisfaction,
which was reported in a prospective non-randomised study. There have been no completed randomised
controlled trials of surgery for type II SLAP lesions. The aims of this participant and observer blinded randomised
placebo-controlled trial are to compare the short-term (6 months) and long-term (2 years) efficacy of labral repair,
biceps tenodesis, and placebo (diagnostic arthroscopy) for alleviating pain and improving function for type II SLAP
lesions.
Methods/Design: A double-blind randomised controlled trial are performed using 120 patients, aged 18 to
60 years, with a history for type II SLAP lesions and clinical signs suggesting type II SLAP lesion, which were
documented by MR arthrography and arthroscopy. Exclusion criteria include patients who have previously
undergone operations for SLAP lesions or recurrent shoulder dislocations, and ruptures of the rotator cuff or biceps
tendon. Outcomes will be assessed at baseline, three, six, 12, and 24 months. Primary outcome measures will be
the clinical Rowe Score (1988-version) and the Western Ontario Instability Index (WOSI) at six and 24 months.
Secondary outcome measures will include the Shoulder Instability Questionnaire (SIQ), the generic EuroQol (EQ-5 D
and EQ-VAS), return to work and previous sports activity, complications, and the number of reoperations.
Discussion: The results of this trial will be of international importance and the results will be translatable into
clinical practice.
Trial Registration: [ClinicalTrials.gov NCT00586742]
Background
The glenoid labrum contributes to stability by increasing
joint concavity and dept of the glenohumeral joint
socket. The superior glenoid labrum of the shoulder
joint is a common site of injury and degeneration1,2,].
Because it is related to the intraarticular insertion of the
long head of the biceps tendon, injuries are common in
throwing athletes. These lesions are often associated
with other shoulder injuries such as rotator cuff tears,
glenohumeral instability or impingement, but they also
may be due to an isolated injury. Snyder et al. used the
term SLAP (superior labrum anterior posterior) to
describe these lesions, and they classified the lesions
into four categories1]. Type II SLAP lesions, which
occur most frequently, are characterised by the com-
bined detachment of the superior labrum and biceps
tendon from the peripheral edge of the glenoid. Surgical
treatment includes reattachment of the labrum with the
use of staples, metal screws, bioabsorbable tacks, and
bioabsorbable anchors. Alternatively, tenodesis of the
biceps tendon is performed, by inserting the tendon in
the bicipital groove of the humeral head, either with
suture anchors or interference screws.
Systematic reviews have analysed the value of diagnostic
tests for SLAP-lesions3-]. Recently, a systematic review
summarised the current evidence about the outcome of
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any medium, provided the original work is properly cited.type II SLAP repair5]. Twelve studies, including 10 to 50
patients each, with at least 2-years of follow-up, were
included; two studies compared two different surgical
methods, two studies were prospective, while ten were ret-
rospective cohort studies. There were no randomised
trials. The percentage of patients classified as good to
excellent varied from 40 to 94%. A return to their previous
level of sports activity varied from 20 to 94%. Despite these
unpredictable results and a lack of evidence from properly
designed studies, shoulder surgeons worldwide perform
type II SLAP repairs.
The aforementioned systematic review recommended
that future studies should be prospective in nature and
they should at least use a longitudinal prospective
cohort design. Because uncontrolled studies have the
potential to provide a distorted view of treatment
results, and non-randomised trials are liable to produce
biased results, we designed a prospective, randomised,
double-blind, sham-controlled trial.
Aims
There are two aims of this randomised placebo-
controlled trial:
1) Compare the short-term (6 months) efficacy of
labral repair, biceps tenodesis, and placebo (diagnos-
tic arthroscopy), for alleviating pain and improving
function for type II SLAP lesions.
2) Compare the long-term (2 years) efficacy includ-
ing the number of reoperations.
Methods/Design
Trial design
This is a participant and observer blinded randomised pla-
cebo-controlled trial with a 2-year follow-up (Figure 1).
Ethics
Ethics approval for this study has been received from
the Ethics Committee Health Region Southeast, Oslo,
Norway.
Participants
Participants will be recruited from general practitioners,
physiotherapists, manual therapists, and from depart-
ments of orthopaedic surgery or physical medicine and
rehabilitation. To increase the awareness of the trial,
health care providers will be invited to attend lectures
on shoulder complaints with a focus on the current
study.
All potential participants will be screened to deter-
mine their eligibility according to the following inclusion
and exclusion criteria. For inclusion, participants should
be aged 18 to 60 years and have a history of type II
SLAP lesions or clinical signs suggesting the presence of
a type II SLAP lesion, and an MR arthrography that
documents the type II SLAP lesion6-]. Finally, the diag-
nosis should be verified at arthroscopy. One experienced
shoulder surgeon and one experienced manual therapist
will perform clinical examinations of the patients.
Patients should have at least one positive sign of a SLAP
lesion (positive O’Brien test], positive Crank test], or
painful apprehension test9]).
A thorough clinical examination will be performed to
exclude possible candidates with differential diagnoses.
The clinical examination will include tests for impinge-
ment10-], pain or weakness on isometric tests of abduc-
tion and external rotation], tests for apprehension and
relocation], scapular dyskinesis], and arthritis of the
acromioclavicular joint15]. Possible candidates will have
an MR arthrography evaluated by a radiologist experi-
enced in shoulder imaging. In addition, conventional x-
rays including outlet view will be conducted to exclude
patients with major acromioclavicular or acromial spurs.
Exclusion criteria include previous surgery for SLAP
lesions, SLAP lesions with concomitant labral cysts16,],
previous surgery for recurrent shoulder dislocation or
SLAP lesions, clinical and radiological signs of arthritis
of the acromioclavicular15,] or the glenohumeral joints,
ruptures of the rotator cuff or biceps tendon11], syno-
vial chondromatosis, fibromyalgia, major somatic or psy-
chiatric disease, and patients that are not able to
understand Norwegian or unwilling to accept one of the
treatment alternatives.
Randomisation
Participants who fulfil the inclusion criteria, and consent
to take part in the trial after they have received the oral
and written information, will be randomised to receive
labral repair, biceps tenodesis, or placebo (diagnostic
arthroscopy) treatment. An independent statistician will
use the method of permuted blocks for random alloca-
tion after the final inclusion criteria are met. Treatment
allocation will be organised by an independent secretary
who distributes sealed opaque numbered envelopes to
the nurse manager in the operation theatre. A nurse will
open the envelope only when a peroperative diagnostic
evaluation has documented a type II SLAP lesion.
Interventions
The patient will be positioned in the lateral decubitus
position with lateral traction and under general anaes-
thesia. A standard posterior portal will be created and a
diagnostic evaluation will be performed. Prior to enter-
ing the glenohumeral joint the subacromial space will be
inspected and evaluated. The subacromial and the gle-
nohumeral evaluations will be documented in a video
created for each patient. An anterior working portal will
Skare et al. BMC Musculoskeletal Disorders 2010, 11:228
http://www.biomedcentral.com/1471-2474/11/228
Page 2 of 6be established in the rotator interval with a spinal nee-
dle for accurate placement. This portal will be used to
probe the superior labrum for documentation of a type-
II SLAP lesion. Arthroscopic diagnostic evaluations and
treatments will be performed by a single experienced
shoulder surgeon.
Following confirmation of a type II SLAP lesion, the
patient will be included in the randomisation procedure.
All patients will receive 20 to 40 ml of a 0.5% local
anaesthetic (Marcaine) at the end of the procedure,
partly to serve as a suprascapular nerve block and partly
to serve as an intraarticular injection. A collar and cuff
sling will be placed before the patient leaves the operat-
ing room.
Placebo (diagnostic arthroscopy)
Patients randomised to diagnostic arthroscopy and post-
operative rehabilitation will comprise the placebo group.
Labral repair
Debridement of the superior glenoid rim will be per-
formed with a motorized shaver from the anterior por-
tal. The bioabsorbable suture anchor will be placed
percutaneously, guided by a spinal needle through the
myotendinous junction of the supraspinatus. From the
percutaneous portal two suture anchors will be placed
Figure 1 Diagram of Recruitment and Participation Process.P l a c e b oi ss h a ms u r g e r y( d i a g n o s t i ca rthroscopy). All groups had standard
postoperative rehabilitation.
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tendon. Sutures will then be made with the use of a
shuttling device from the anterior portal. Fixation will
be secured with a sliding knot and three half-hitches in
alternating directions. Eventually, an anterior anchor
will be placed through the anterior portal. No other pro-
cedures will be performed.
Biceps tenodesis
Although other arthroscopic methods are described, we
routinely use a mini-open technique for biceps tenodesis
(14). For exact positioning of the biceps tendon, a spinal
needle will be placed under arthroscopic vision, as far
laterally and central as possible in the biceps tendon.
A tenotomy will be performed at the biceps labrum
junction. The rest of the procedure will be performed
mini-open with a 2 cm skin incision with the spinal nee-
dle in the centre. In order to identify and open the
biceps pulley the deltoid will be split along the muscle
fibers. The biceps tendon will be identified and lifted
outside of the bicipital groove. The groove will be deb-
rided, and a metal double suture anchor with needles
will be placed in the groove. One of the limbs of each
suture will be placed as a simple stitch to secure sliding
of the knot, and the second limb will be passed two
times to secure the fixation. Approximately 2 cm of the
tendon will be excised and the pulley and skin will be
closed. No other procedures will be performed.
Post-operative rehabilitation
Patients in all three groups will have standardised, but
individually adjusted rehabilitation. Elbow, wrist, and fin-
ger mobilisation and gentle pendulum exercises will be
conducted, starting on the first postoperative day. A sling
will be used for three weeks. Local physiotherapists or
manual therapists, who are given a written detailed
description of the methods and progression, will provide
treatment to patients when they are discharged from the
hospital. Passive techniques like massage and stretching
along with core stability exercises and general physical
training will be used during the first three weeks. Exercises
to normalise the gleno-humeral rhythm and improve
coordination and mobility will be given using sling exer-
cise therapy17]. Exercises to improve functional stability
and muscle strength of the rotator cuff and scapular stabi-
lising muscles will be progressively emphasised after six
weeks. Sports- or job-specific rehabilitation will be given
on an individual basis, usually starting three months post-
operatively. Rehabilitation will continue for three to six
months and will include 12-16 sessions with a therapist
and about 20 sessions of self-administered exercises.
Outcome assessment
Baseline data will include gender, age, smoking, previous
treatment, duration of symptoms, MR arthrography and
conventional x-rays including outlet view, and primary
and secondary outcome measures.
The same blinded observer will assess all participants
after the procedure at three, six, 12 and 24 months.
Pain, health related quality of life, complications, and a
return to sports and work will be assessed at each time
point. Blinding will be evaluated by asking the patients
about which treatment they perceive to have received.
Pain during activity and pain at rest (over the last
week) will be measured on a 0-100 visual analogue scale
(VAS), comprising a horizontal line labelled no pain at
one end and worst imaginable pain at the other end.
A range of standardised, generic and specific self-
report health-related quality of life measures and the
clinical Rowe Score will be used. To our knowledge out-
come measures have not been particularly evaluated for
patients with SLAP lesions. The primary outcome mea-
sures in the present trial will be the 1988 version of the
Rowe Score18,] and the Western Ontario Instability
Index (WOSI)19]. The latter has been professionally
translated to Norwegian.
The Rowe Score was first described in 1978 for use in
patients after they were administered the Bankart proce-
dure for anterior shoulder dislocation20]. Four different
versions exist. We will use the 1988 version. The obser-
ver will question the patient about function and pain,
and assess their stability, muscle strength, and range of
motion. The Rowe Score can be weighted using either
pain or stability as the main problem. Because pain is the
main complaint in patients with type II SLAP lesions, we
will weight pain as 25 points. Pain has five levels ranging
from severe (0 points) to none (25). Stability has five
levels ranging from recurrent dislocation (0) to normal
shoulder stability, which includes a negative apprehen-
sion test (15). Function has five response alternatives
from total disability (0) to normal function with no lim-
itation in daily living, sports, or work (25). Range of
motion is evaluated for abduction/forward flexion, inter-
nal rotation and external rotation, and it is categorised
from a full range of motion (25) to less than 30° of
motion (0). Muscle strength will be measured by a spring
gauge, and results will be compared to the opposite
shoulder and categorised from normal (10) to poor (0).
The best achievable score is 100. Results are commonly
classified into four categories: poor (39 points or less),
f a i r( 4 0t o6 9p o i n t s ) ,g o o d( 7 0t o8 9p o i n t s ) ,a n de x c e l -
lent (90 to 100 points).
The WOSI is a disease-specific health related quality
of life instrument developed and validated for use in
patients with shoulder instability. It comprises 21 items
representing four domains. The first domain covers phy-
sical symptoms and contains 10 items. The remaining
domains are sports, recreation, and work (four items),
lifestyle (four items), and emotions (three items). Each
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visual analogue scale. The worst score possible is 2100.
This signifies that the patient has an extreme decrease
in shoulder-related health-related quality of life.
The Shoulder Instability Questionnaire (SIQ) is a dis-
ease-specific health related quality of life instrument
validated for use in patients with shoulder instability21].
It includes 12 questions (1-5 points each) with possible
scores from 12 (best function) to 60 (worst function).
The EuroQuol (EQ-5 D and EQ-VAS) is a standard
generic health-related quality of life instrument22]. The
EQ-5 D measures five domains (Mobility, Self-Care,
Usual Activities, Pain/Discomfort, and Anxiety/Depres-
sion); each has three levels, ranging in severity from no
problem, to some problem, or an extreme problem.
Responses are transformed to an index and then classi-
fied into 243 (3
5) health states, with the best imaginable
state (1.0) representing the highest level of functionality.
Sickness absence data will be collected from the
National Social Security Institution.
Sample size
The main end-points are six and 24 months12]. From
clinical experience we estimated that the smallest clini-
cally important detectable difference is 10 points on the
100 points Rowe Score. Assuming that the largest differ-
ence between treatments willb e1 0u n i t s ,w es i m u l a t e d
multiple scenarios and estimated the standard deviation
between means to be 14.6 units. To detect this differ-
ence between treatment groups (SD = 15, a =0 . 0 5 ,b =
0.80, One-Way ANOVA) our study will require 36
patients in each group. Assuming some patients drop-
out, we plan to include 40 patients in each group.
Planned statistical analysis
Treatment groups will be examined for comparability at
baseline with respect to demographic and prognostic
factors. All eligible patients, regardless of their compli-
ance with protocol (analysis by intention-to-treat) will
be included in the main analyses. To asses the effect of
the interventions on the endpoints (six and 24 months),
analysis of covariance (ANCOVA) will be performed
using the baseline values as one of the covariates. Stan-
dard regression assumptions will be assessed using diag-
nostic plots, Jacknife residuals, Cook’sd i s t a n c e s ,a n d
Variance inflation Factor (VIF). We will adjust for an
eventual imbalance at the baseline. Corresponding post-
hoc tests (Tukey’s test) will be performed. To evaluate
the time-course at three, six, 12, and 24 months,
repeated measures will be analyzed using linear mixed
models. If the number of missing values exceeds 10% in
one of the groups, multiple imputations will be used to
estimate the missing values. To assess the robustness of
our findings the analysis will be performed with and
without the imputed values.
Discussion and conclusion
Surgery for type II SLAP lesions are performed world-
wide, but published reports suggest that outcome is dif-
ficult to predict. Interventions that effectively reduce
pain, improve function, and allow patients to return to
sports and work are lacking. Promising results are pub-
lished for both biceps tenodesis and labral repair5,23],
but the lack of a randomised design, standardised inclu-
sion and exclusion criteria, and small study sizes, may
bias these conclusions.
Few clinical trials in orthopaedic surgery include sham
or placebo treatments. Two trials compared vertebro-
plasty24-] with placebo in patients with osteoporotic
vertebral compression fractures, and one trial compared
arthroscopic lavage, debridement, and placebo in
patients with osteoarthritis of the knee26]. Neither of
these trials found that the surgical procedure was effec-
tive compared with the placebo. These trials emphasise
the importance of including a placebo intervention in a
randomised trial in order to improve present knowledge
about mechanisms for pain reduction after surgical
procedures.
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